Company Overview of Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase II trials to treat genital herpes infections. It is also developing GEN-004, a Phase II vaccine for the prevention of pneumococcal infections; GEN-001 that is in pre-clinical product candidate for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-...
100 Acorn Park Drive
Cambridge, MA 02140
Founded in 2006
Key Executives for Genocea Biosciences, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $393.6K
Chief Financial Officer and Secretary
Total Annual Compensation: $285.2K
Chief Medical Officer
Total Annual Compensation: $366.1K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2014.
Genocea Biosciences, Inc. Key Developments
Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003
May 20 15
Genocea Biosciences, Inc. announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of dosing, the best dose of 60 µg per protein /75 µg of Matrix-M2TM adjuvant demonstrated a highly statistically significant (p<0.0001) 55% reduction from baseline in the viral shedding rate, the primary endpoint of the trial and a measure of anti-viral activity. All dose combinations tested, including the successful 30 µg per protein /50 µg of adjuvant dose from the prior Phase 1/2a trial, demonstrated a statistically significant viral shedding rate reduction versus baseline and only the lowest dose combination did not demonstrate a statistically significant reduction versus placebo. In a planned secondary analysis to assess impact on patient-reported genital lesion rates, a self-assessed measurement of clinical disease, all dose groups, including the placebo group, demonstrated a statistically significant reduction from baseline. The Phase 2 study showed that GEN-003 was generally safe and well tolerated by patients, with no serious adverse events related to the vaccine. Safety data throughout the trial is monitored by an independent data safety monitoring board. Although reactogenicity increased with adjuvant dose, there was no difference in discontinuations in patient dosing due to adverse events across the different treatment arms.
Genocea Biosciences, Inc. - Special Call
May 20 15
To discuss positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes
Genocea Biosciences, Inc Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015
May 7 15
Genocea Biosciences, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported grant revenue of $0.121 million. Loss from operations was $11.777 million against $6.373 million a year ago. Net loss attributable to common stockholders was $12.084 million or $0.64 per basic and diluted share against $7.509 million or $0.76 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 20, 2014